Previous Close | 22.7 |
1-Year Change | -38.32% |
6-Months Change | -33.59% |
3-Months Change | -2.62% |
Moving Avg (50d) | 24.802 |
Moving Avg (200d) | 32.296 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.07M |
Beta (3-Years) | 1.3 |
Revenue Growth (ttm) | 304.92% |
Net Profit Margin (ttm) | -2.86% |
Return On Assets (ttm) | -0.04% |
EPS (ttm) | -2.65 |
PE Ratio (ttm) | -8.57 |
Dividend Yield | % |
Asset Description: | Celldex Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2025-02-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
22.246 | 21.565 | 21.111 | 20.43 | 19.295 | 18.16 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |